Denali Advisors LLC Purchases New Position in SIGA Technologies, Inc. (NASDAQ:SIGA)

Denali Advisors LLC purchased a new stake in shares of SIGA Technologies, Inc. (NASDAQ:SIGA) during the second quarter, HoldingsChannel.com reports. The firm purchased 239,100 shares of the company’s stock, valued at approximately $1,815,000.

Other hedge funds also recently bought and sold shares of the company. DekaBank Deutsche Girozentrale purchased a new position in SIGA Technologies during the 2nd quarter valued at about $40,000. Steward Partners Investment Solutions LLC bought a new stake in shares of SIGA Technologies in the 4th quarter worth approximately $58,000. Bayesian Capital Management LP bought a new stake in shares of SIGA Technologies in the 1st quarter worth approximately $97,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of SIGA Technologies by 38.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,684 shares of the company’s stock worth $104,000 after purchasing an additional 3,829 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new stake in shares of SIGA Technologies in the 1st quarter worth approximately $105,000. Hedge funds and other institutional investors own 55.40% of the company’s stock.

SIGA Technologies Trading Up 1.1 %

SIGA stock opened at $7.99 on Tuesday. The stock has a market capitalization of $570.25 million, a PE ratio of 7.26 and a beta of 0.91. SIGA Technologies, Inc. has a 12-month low of $4.26 and a 12-month high of $12.83. The stock’s 50 day simple moving average is $9.05 and its 200 day simple moving average is $8.25.

SIGA Technologies (NASDAQ:SIGA) last announced its earnings results on Thursday, August 1st. The company reported $0.03 earnings per share for the quarter. The business had revenue of $21.81 million during the quarter. SIGA Technologies had a net margin of 48.55% and a return on equity of 51.40%. During the same quarter in the prior year, the firm posted ($0.04) earnings per share. On average, research analysts predict that SIGA Technologies, Inc. will post 1.01 earnings per share for the current year.

SIGA Technologies Company Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.